Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 7;50(S Pt 1):1-6.
doi: 10.15586/aei.v50iSP1.535. eCollection 2022.

Hereditary angioedema in children and adolescents

Eli Mansour  1 , Camila L Veronez  2   3 , Timothy Craig  4 , Anete Sevciovic Grumach  5
Affiliations

Hereditary angioedema in children and adolescents

Eli Mansour et al. Allergol Immunopathol (Madr). .

Abstract

Hereditary angioedema is a genetic disease with autosomal dominant inheritance and, in most cases, caused by C1 inhibitor deficiency. Patients present with recurrent edema affecting sub-cutaneous and mucus membranes with variable onset and severity. More than 50% of patients may become symptomatic before 10 years of age. Family history can help with the diagnosis; however, approximately 25% of the cases are de novo mutations. Biochemical diagnosis should be delayed until after 1 year of age. Children were often excluded from advances in therapy for hereditary angioedema since most of the new medicines were tested in adults and thus excluded by the Food and Drug Administration (FDA) and other agencies for approval to be used in children. Treatment of attacks is available for the pediatric patient; however, barriers still exist for the use of long-term prophylaxis in young children. © 2022 Codon Publications. Published by Codon Publications.

Keywords: C1 inhibitor; Hereditary angioedema; attack; child; pediatric; prophylaxis; treatment.

PubMed Disclaimer

References

    1. 1. Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hébert J, Kanani A, et al. The International/Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2019 Nov 25;15:72. 10.1186/s13223-019-0376-8 - DOI
    1. 2. Farkas H, Martinez-Saguer I, Bork K, Bowen T, Craig T, Frank M, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017 Feb;72(2):300–313. 10.1111/all.13001 - DOI
    1. 3. Grivcheva-Panovska V, Giannetti B. Hereditary angioedema attack in utero and treatment of the mother and fetus. Mayo Clin Proc Innov Qual Outcomes. 2020 Aug 22;4(5):595–600. 10.1016/j.mayocpiqo.2020.06.004 - DOI
    1. 4. Abdon Barbosa A, de Oliveira Martins R, Martins R, Grumach AS. Assessment on hereditary angioedema burden of illness in Brazil: a patient perspective. Allergy Asthma Proc. 2019 May 1;40(3):193–197. 10.2500/aap.2019.40.4207 - DOI
    1. 5. Banerji A, Li Y, Busse P, Riedl MA, Holtzman NS, Li HH, et al. Hereditary angioedema from the patient’s perspective: a follow-up patient survey. Allergy Asthma Proc. 2018 May 1;39(3):212–223. 10.2500/aap.2018.39.4123 - DOI

Substances